Showing results (21-30 of 37) with videos related to
Sort By:
Pageof 4
Scientific Reports|August 9, 2024
Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapyLucilla D'Abundo, Cristian Bassi, Elisa Callegari, et al.Oncotarget|June 20, 2015
miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse modelAntonella Bresin, Elisa Callegari, Lucilla D'Abundo, et al.Frontiers in Genetics|May 1, 2013
miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAsLaura Lupini, Cristian Bassi, Manuela Ferracin, et al.The Journal of Pathology|January 21, 2012
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2Francesca Fornari, Maddalena Milazzo, Pasquale Chieco, et al.Journal of Medicinal Chemistry|January 10, 2019
Evaluation of Amides, Carbamates, Sulfonamides, and Ureas of 4-Prop-2-ynylidenecycloalkylamine as Potent, Selective, and Bioavailable Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5Davide Graziani, Silvia Caligari, Elisa Callegari, et al.Plos One|September 27, 2013
Anti-tumor activity of a miR-199-dependent oncolytic adenovirusElisa Callegari, Bahaeldin K Elamin, Lucilla D'Abundo, et al.Cancer Research|February 5, 2020
MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular CarcinomaLaura Gramantieri, Daniela Pollutri, Martina Gagliardi, et al.Molecular Oncology|May 23, 2020
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancerRoberta Roncarati, Laura Lupini, Elena Miotto, et al.Molecular Therapy. Nucleic Acids|January 15, 2019
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver CancerElisa Callegari, Marco Domenicali, Ram Charan Shankaraiah, et al.Journal of Clinical Medicine|February 13, 2026
The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory AnalysisGiuseppe Bronte, Aldo Carnevale, Antonella Ciancetta, et al.Pageof 4